The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Lenalidomide for second-line treatment of advanced hepatocellular cancer (HCC): A Brown University Oncology Group phase II study.
Howard Safran
Research Funding - Celgene
Kevin Charpentier
No relevant relationships to disclose
Andreas Kaubisch
No relevant relationships to disclose
Gregory Dubel
No relevant relationships to disclose
Kimberly Perez
No relevant relationships to disclose
Katherine E. Faricy-Anderson
No relevant relationships to disclose
Thomas J. Miner
No relevant relationships to disclose
Joel Victor
No relevant relationships to disclose
Angela Marie Taber
No relevant relationships to disclose
Pamela Bakalarski
No relevant relationships to disclose
Patti Wingate
No relevant relationships to disclose
Kalyan C Mantripragada
No relevant relationships to disclose
Denise Luppe
No relevant relationships to disclose
Kayla Rosati
No relevant relationships to disclose
Joseph Espat
No relevant relationships to disclose
Debora Isdale
No relevant relationships to disclose
Yoko Eng
No relevant relationships to disclose
Diane Martel
No relevant relationships to disclose
David Berz
No relevant relationships to disclose
Jack Wands
Research Funding - Celgene